Area of research
Pulmonary and Respiratory Medicine · Molecular Biology
Research interest
Research focused on Formoterol and Sorafenib, with related work in Apolipoprotein B, Leukemia, Clenbuterol. Notable publications include 'Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status', 'Structural and pharmacological basis for the induction of mitochondrial biogenesis by formoterol but not clenbuterol', and 'Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib'.
A human iPSC-derived hepatocyte screen identifies compounds that inhibit production of Apolipoprotein B
Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status
Genetic Variants of <i>VEGFA</i> and <i>FLT4</i> Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
Structural and pharmacological basis for the induction of mitochondrial biogenesis by formoterol but not clenbuterol